MDG1.DE Medigene AG XETRA -27.64% premarket 13 Mar 2026: Oversold bounce alert

MDG1.DE stock plunged -27.64% in pre-market trade on 13 Mar 2026, leaving the share at €0.13 and creating an oversold bounce setup. Volume spiked to 189,470 shares, nearly 4.39x average, signalling capitulation near the session low of €0.08. We view this as a high-risk short-term bounce candidate, driven by a stretched technical move rather than fresh positive fundamentals. Traders should weigh sharply negative trailing metrics — EPS -1.21 and PE -0.11 — against a strong current ratio of 2.53 before sizing positions.

MDG1.DE stock pre-market price action and liquidity

Medigene AG (MDG1.DE) on XETRA opened €0.16 and printed a day low at €0.08 with a close-level price of €0.13 (EUR 0.1335). The intraday volume of 189,470 versus an average of 43,152 shows a rel. volume of 4.39, indicating execution risk but also offering a short-term bounce opportunity for nimble traders.

MDG1.DE stock fundamentals and valuation

Fundamentals remain weak: EPS is -1.21, trailing PE is -0.11, price-to-book is 0.08, and market cap is roughly €1.97m. The company reports healthy cash per share €1.36 and a current ratio of 2.53, which provide liquidity buffers even as operating cashflow per share is negative at -1.23.

MDG1.DE stock technicals and oversold signals

Technically the stock trades far below its 50-day average €1.41 and 200-day average €1.66, a classic oversold gap after multi-quarter declines (YTD -86.78%, 1Y -94.51%). Short-term momentum readings and the very high relative volume suggest a bounce is likely, but trend indicators still favour downside until volume normalises.

Meyka AI rates MDG1.DE with a score out of 100

Meyka AI rates MDG1.DE with a score of 61.89 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects weak profitability but adequate liquidity, and it is informational only and not financial advice.

MDG1.DE stock risks, catalysts and sector context

Key risks include continuing clinical setbacks, persistent negative EPS, and thin market capitalisation that magnifies volatility. Catalysts for a sustainable recovery would be positive clinical updates or partnership news. The Healthcare sector in Germany is mixed with an average current ratio near 2.74, so Medigene’s liquidity is roughly in line with peers.

Short-term oversold bounce trade idea for MDG1.DE stock

For traders: consider a small, disciplined entry size with a tight stop loss near €0.10 and a first target in the €0.22–€0.30 range to capture an oversold rebound. Monitor volume, regulatory updates, and the next company announcement date. Use the Meyka stock page for live watchlists: Meyka MDG1.DE page.

Final Thoughts

MDG1.DE stock looks set for a short-term oversold bounce after the pre-market drop to €0.13 (EUR 0.1335), driven by a surge in selling volume and extreme deviation from moving averages. Meyka AI’s forecast model projects a near-term rebound to €0.25, implying an upside of 87.30% versus the current price (EUR 0.1335). We also model a conditional 12-month recovery scenario to €0.90, implying a 574.27% upside if clinical and partnership catalysts reappear. These projections are model-based and not guarantees; the immediate setup suits tactical traders seeking a high-risk, event-driven bounce while longer-term investors must resolve fundamental uncertainty. Confirm liquidity and news flow before action and consult the company site for corporate updates: Medigene and the company LinkedIn page for releases.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.